Nature Cancer Summary: ctDNA as an early predictor of therapy response
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Beth’s Colorectal Cancer Story
Read Article
-
Treatment response monitoring for people receiving immunotherapy for advanced or metastatic melanoma
Read More
-
Learn How Signatera Helped LuAnn and Her Doctor Monitor Her Response to Immunotherapy Treatment
Read More
-
Better Together: CtDNA and Germline Testing
Watch Video
-
Webinar & Panel Discussion: New Data on how ctDNA is Evolving Oncology Patient Management and Drug Development
Watch Video
-
How Can Real World Clinico Genomics Data Accelerate Drug Development
Watch Video
-
Gschwend et al Overall survival by circulating tumor DNA status in patients with post-operative muscle-invasive urothelial carcinoma treated
View Poster
-
Panel Discussion: Optimizing Patient Selection & Prediction of Therapy Efficacy in Clinical Trials with ctDNA
Watch Video
-
Comparison of the Predictive and Prognostic Significance of Circulating Tumor DNA in Patients with High Risk HER2-negative Breast Cancer
View Poster
-
Signatera for Bladder Cancer
Read Article
-
Advances in ctDNA-Guided Treatment Decisions in Urothelial Carcinoma
Watch Video
-
Personalized MRD Assessment to Inform Treatment Decisions in Solid Tumors
Watch Video
-
Power Drug Development with Real-World Data
Read More
-
Optimize Clinical Development with Signatera
Read More
-
Know the Facts About Bladder Cancer
Read Article
-
Tissue Sample Collection Instructions
Overview document on how Signatera collections a FFPE sample.
Read More
-
Build early evidence that your investigational drug is working
Watch Video
-
Early reduction in ctDNA is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma patients
Read More
-
Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients
Read More
-
Loading More...
